

30 Jan 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: J&J considers bold M&A moves; a prominent new CEO for Galapagos; Biogen's interim leader talks to *Scrip*; a view on Biogen and M&A; and a look at Astellas' digital shift plans.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 28 January 2022, including: [Johnson & Johnson](#) considers bold M&A moves; a prominent new CEO for [Galapagos NV](#); [Biogen, Inc.](#)'s interim leader talks to *Scrip*; a view on Biogen and M&A; and a look at [Astellas Pharma, Inc.](#)'s digital shift plans.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[J&J, Flush With Cash, Has Flexibility To Be 'Bolder' On M&A, CEO Duato Says](#)" - Scrip, 25 Jan, 2022.)

(Also see "[Pharma R&D Legend Stoffels To Take Helm At Galapagos](#)" - Scrip, 27 Jan, 2022.)

(Also see "[Biogen's Singhal On Stepping Into R&D Leadership Shoes Amid Aduhelm Controversy](#)" - Scrip, 26 Jan, 2022.)

(Also see "[Stock Watch: Biogen, Blood In The Water](#)" - Scrip, 24 Jan, 2022.)

(Also see "[Astellas Positions Patients At Center Of Digital Push](#)" - Scrip, 26 Jan, 2022.)

[Click here to explore this interactive content online](#) ✨